Related Experiment Videos

Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro

S Antoniotti1, P Maggiora, C Dati

  • 1Dipartimento di Biologia Animale, University of Torino, Italy.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
PubMed

Insights

Tamoxifen, an anti-oestrogen drug, enhances c-erbB-2 expression in oestrogen receptor-positive breast cancer cells, inhibiting their growth. This finding may explain treatment failures in some breast cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oestrogens inhibit c-erbB-2 proto-oncogene expression in human breast cancer cells.
  • c-erbB-2 proto-oncogene plays a crucial role in cell proliferation and cancer development.

Purpose of the Study:

  • To investigate the effect of tamoxifen on c-erbB-2 expression in oestrogen receptor-positive and negative breast cancer cells.
  • To understand the role of tamoxifen in regulating c-erbB-2 and its impact on cell growth.

Main Methods:

  • Cell culture of oestrogen receptor-positive and negative human breast cancer cells.
  • Analysis of c-erbB-2 mRNA and protein expression levels.
  • Assessment of cell growth inhibition by tamoxifen.

Main Results:

  • Tamoxifen demonstrated full anti-oestrogenic activity, enhancing c-erbB-2 expression in oestrogen receptor-positive cells.
  • Tamoxifen reversed oestrogen's inhibitory effect on c-erbB-2 and strongly inhibited cell growth.
  • Tamoxifen had no effect on c-erbB-2 expression or growth in oestrogen receptor-negative cells.

Conclusions:

  • Tamoxifen's regulation of c-erbB-2 expression contributes to its anti-cancer effects in oestrogen receptor-positive breast cancer.
  • These findings may elucidate the mechanisms behind tamoxifen therapy failure in certain breast cancer cases.

Related Concept Videos